Literature DB >> 34743311

Keeping Pace with Adolescent Asthma: A Practical Approach to Optimizing Care.

Zai Ru Cheng1, Yi Hua Tan2,3, Oon Hoe Teoh2,3, Jan Hau Lee4,3.   

Abstract

Known for their pre-occupation with body image, self-identity creation, peer acceptance, and risk-taking behaviors, adolescents with asthma face unique challenges. Asthma is a heterogeneous disease and accurate diagnosis requires assessment through detailed clinical history, examination, and objective tests. Diagnostic challenges exist as many adolescents can present with asthma-like symptoms but do not respond to asthma treatment and risk being mis-diagnosed. Under-recognition of asthma symptoms and denial of disease severity must also be addressed. The over-reliance on short-acting beta-agonists in the absence of anti-inflammatory therapy for asthma is now deemed unsafe. Adolescents with mild asthma benefit from symptom-driven treatment with combination inhaled corticosteroids (ICS) and long-acting beta-agonist (LABA) on an as-required basis. For those with moderate-to-persistent asthma requiring daily controller therapy, maintenance and reliever therapy using the same ICS-LABA controller simplifies treatment regimes, while serving to reduce exacerbation risk. A developmentally staged approach based on factors affecting asthma control in early, middle, and late adolescence enables better understanding of the individual's therapeutic needs. Biological, psychological, and social factors help formulate a risk assessment profile in adolescents with difficult-to-treat and severe asthma. Smoking increases risks of developing asthma symptoms, lung function deterioration, and asthma exacerbations. Morbidity associated with e-cigarettes or vaping calls for robust efforts towards smoking and vaping cessation and abstinence. As adolescents progress from child-centered to adult-oriented care, coordination and planning are required to improve their self-efficacy to ready them for transition. Frequent flare-ups of asthma can delay academic attainment and adversely affect social and physical development. In tandem with healthcare providers, community and schools can link up to help shoulder this burden, optimizing care for adolescents with asthma.
© 2021. The Author(s).

Entities:  

Keywords:  Adolescents; Asthma; Smoking; Transition

Year:  2021        PMID: 34743311      PMCID: PMC8571974          DOI: 10.1007/s41030-021-00177-2

Source DB:  PubMed          Journal:  Pulm Ther        ISSN: 2364-1754


Key Summary Points

Introduction

The ‘waters of adolescence’ are navigated by individuals 10–19 years old [1]. Up to 12% of adolescents worldwide suffer from chronic disease [2] and asthma continues to afflict this age group. Widely considered a disease of childhood with reduction in symptom flare-ups with age [3], adolescents still experience significant asthma morbidity [4] due to unique challenges posed whilst entering this phase and during transition to adult care [5]. Peer acceptance, self-identity, and experimentation form a web of psychosocial factors that interlace with the biological changes of puberty to have a profound impact on adolescent health and well-being [6]. This necessitates the adoption of a developmentally staged management approach in adolescents with asthma [7]. This narrative review discusses diagnostic conundrums, pitfalls associated with over- and under-reporting of asthma symptoms, and the impact of developmental stages on adolescent asthma control. Factors associated with difficult-to-treat and severe asthma in adolescence and blind spots during transition to adult-oriented care are also highlighted. This article is based on reviews of current guidelines and literature and did not involve any new studies with human participants or animals performed by any of the authors.

Conundrums Associated with Diagnosing Adolescent Asthma

Table 1 lists common mimickers of asthma in an adolescent. Asthma is highly heterogeneous and symptoms and control vary with the passage of time [8], on the back of a multitude of triggers [9]. Diagnostic uncertainty can arise when an asthmatic child does not demonstrate significant spirometry bronchodilator reversibility (increase in forced expiratory volume in 1 s (FEV1) by ≥ 12%), especially if baseline pre-bronchodilator lung function test is normal [10]. The gathering of supportive evidence for asthma (e.g., response to previous inhaled corticosteroids (ICS) therapy, self-reported bronchodilator response and atopic status) over time may increase diagnostic confidence.
Table 1

Mimickers of asthma in adolescents and useful assessment modalities

OnsetCategoryDiagnosisWhen to suspectUseful assessment modalities
AcuteAirway foreign bodyAbrupt symptom onset, unilateral wheeze, history of chokingBronchoscopy, chest X-rayAirway foreign body
Acute on chronicPhysical fitness and perceptionNormal breathlessness associated with exercise, physical deconditioningSedentary lifestyle, inability to cope with increased intensity of physical activitySpirometry, exercise challenge test
Dysfunctional breathingILOAnxious, elite athleteLaryngoscopy during episodes showing paradoxical vocal cord closure, Spirometry with inspiratory loops HEADSS assessment
BPD e.g., hyperventilation, periodic deep sighingTachypneic, agitated, sense of doom, chest pain, paresthesia, lightheadedness
ChronicRespiratoryAllergic rhinitisAtopic historySkin prick tests
Protracted bacterial bronchitisChronic wet cough that responds to antibiotic courses but not to asthma treatmentSputum culture, flexible bronchoscopy, and BAL
Suppurative lung disease (cystic fibrosis, bronchiectasis)Chronic persistent wet cough, malabsorption, failure to thrive, digital clubbing, recurrent chest infections, airway bacterial colonizationSweat chloride, genetic testing, sputum culture, spirometry, chest CT
Interstitial lung diseaseTachypnea, hypoxemia, crackles, cough, poor growthChest CT, flexible bronchoscopy and BAL, lung biopsy, genetic testing
Primary ciliary dyskinesiaChronic rhinosinusitis and otitis media, daily wet cough, laterality defectsGenetic testing, chest CT, ciliary brushings
Airway malacia, extrinsic intrathoracic airway compressionHistory of surgical correction for tracheo-esophageal fistula or vascular ring, associated stridor, exertional wheezeFlexible bronchoscopy
CardiacPulmonary hypertension, cardiac arrhythmias, valvular diseaseSyncope, poor effort tolerance, family history of sudden cardiac death2D-echocardiography, ECG, CT angiogram
Vascular malformationsStridor
Cardiac failureWheeze and bibasal crepitations
HematologyAnemia secondary to menorrhagia and other causesGradual worsening of effort tolerance, heavy or prolonged menstrual bleeding, personal and family history of bleeding tendenciesFull blood count, peripheral blood film, serum iron biochemistry panel

ILO inducible laryngeal obstruction, BPD breathing pattern disorder, HEADSS home, education/employment, eating/exercise, activities, drugs, sexuality, suicide/depression (comprehensive history taking), BAL bronchoalveolar lavage, CT computed tomography, ECG electrocardiogram

Mimickers of asthma in adolescents and useful assessment modalities ILO inducible laryngeal obstruction, BPD breathing pattern disorder, HEADSS home, education/employment, eating/exercise, activities, drugs, sexuality, suicide/depression (comprehensive history taking), BAL bronchoalveolar lavage, CT computed tomography, ECG electrocardiogram Of particular interest in adolescents, patients who report breathlessness and noisy breathing during rest or exercise may have inducible laryngeal obstruction (ILO) [11]. ILO that occurs during exercise can be due to exercise-induced laryngeal obstruction (EILO) [12]. This oft-under-recognized entity presents with inspiratory stridor, throat tightness, maximal breathlessness during exertion and resolution upon rest [13], or changes in voice post-exercise [14]. EILO often affects elite athletes between 11 and 18 years old, especially those with underlying anxious personalities [15, 16]. Diagnosing EILO involves continuous fiber-optic laryngoscopy during exercise to visualize inappropriate laryngeal closure [17]. Few are accustomed or willing to tolerate this. EILO is often confused with exercise-induced bronchospasm (EIB), which requires a fall in FEV1 ≥ 10% and > 200 ml from baseline during an exercise challenge test [18]. These two conditions rarely co-exist [19] and have distinct clinical features [20] (Table 2).
Table 2

Key features differentiating EILO and EIB. Table adapted from [12]

Key presenting featuresEILOEIB
Chest tightness ±  + 
Throat tightness+ 
Inspiratory stridor + 
Expiratory wheeze+ 
Usual triggersAerobic exercise, hot or cold temperatures, airway irritation, extreme emotion
Co-morbiditiesGERD, post-nasal dripAllergens
Number of triggersUsually single triggerUsually many
Usual onset of symptoms after initiation of physical activity (min)< 5> 5–10
Recovery period (min)5–1015–60
Bronchodilator response or improvement with systemic corticosteroids + 
Night awakening with symptoms + 
Female disposition + 

EIB Exercise-induced bronchospasm, GERD Gastro-esophageal reflux disease

Key features differentiating EILO and EIB. Table adapted from [12] EIB Exercise-induced bronchospasm, GERD Gastro-esophageal reflux disease

Over- and Under-Reporting of Asthma Symptoms: Recognizing and Addressing Pitfalls

Discrepancy can exist between perceived severity of symptoms and clinical assessments. Occasionally, reported “severe” symptoms are attributed to psycho-somatic manifestations in adolescents when objective assessments for asthma diagnosis are non-corroborative and response to treatment inconsistent [21]. The interplay between chronic disease and psychosocial functioning [22] must be discussed with the family and recognized as a potential contributor to erroneous symptom attribution or hyper-vigilance to asthma-related emotional cues of stress and anxiety [23]. Conversely, under-recognition of asthma severity occurs more commonly in adolescents. Some adolescents normalize and accept their chronic asthma symptoms over time, while others adopt coping strategies (e.g., minimizing physical activity). Some under-report asthma symptoms or reliever medication use to avoid escalation of their controller therapy. As such, reversible airway obstruction and airway inflammation are often demonstrated on objective tests even when the patient reports no symptoms. The asthma control review should be done in a non-judgmental manner, involving a mix of open-ended questions and specific clarifications. Where available, the addition of regular lung function tests adds objectivity to the assessment of asthma control and severity (Table 3).
Table 3

Lung function tests with utility for assessment of adolescents with asthma

Name of testResults supporting variable expiratory airflow limitation
SpirometryLow FEV1 with FEV1/FVC ratio below lower limit of normal (in children, < 0.9)
FEV1 increases from pre-bronchodilator value by ≥ 12%
Exercise challenge testFall in FEV1 of ≥ 10% and > 200 ml from baseline

FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, FeNO fractional exhaled nitric oxide, ppb parts per billion

Lung function tests with utility for assessment of adolescents with asthma FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, FeNO fractional exhaled nitric oxide, ppb parts per billion Adolescents prescribed daily ICS are often non-concordant [24]. The need for different inhaler devices for both controller and reliever therapies adds to this problem. A major change in the Global Initiative for Asthma (GINA) [25] 2019 guidelines paved the way for adolescents with mild asthma to choose between daily low dose ICS or as-needed symptom-driven use of ICS combined with long-acting beta-agonist (LABA) in the form of budesonide–formoterol Symbicort® dry powder inhaler (DPI). This change was supported by the results of the ‘SYmbicort Given as needed in Mild Asthma’ (SYGMA-2) trial [26, 27], which showed non-inferiority of budesonide–formoterol DPI as a reliever for the rate of annualized severe asthma exacerbations in patients ≥ 12 years, compared to maintenance low-dose budesonide with as-required short-acting beta-agonists (SABA). As-needed treatment with budesonide–formoterol was shown to prevent exacerbations and significantly reduced median daily ICS dose. The preceding SYGMA-1 [28] trial also showed that as-needed budesonide–formoterol combination was superior to as-needed terbutaline for asthma symptom control and prevention of exacerbations. This heralded a fundamental shift away from solely using as required SABA in mild asthma, a practice now deemed unsafe [29]. Adolescents aged ≥ 12 years with moderate-to-severe persistent asthma require daily controller therapy. Following the evolution of guidelines up to GINA 2021, there are currently two treatment tracks to choose from: budesonide–formoterol prescribed in a single inhaler for use in both ‘Maintenance And Reliever Therapy’ (MART), or higher-dose ICS-LABA as controller and SABA for reliever [30]. An asthma action plan based on MART that escalates treatment using the same controller inhaler based on self-recognition of symptoms is welcomed from a patient perspective [31]. MART reduces exacerbation risk that continues to exist even in the mildest of asthma phenotypes, simplifying treatment regimens and reducing acute care visits [32].

Difficult-to-Treat and Severe Asthma During Adolescence

Asthma may seem “difficult to treat” due to modifiable factors of poor adherence, smoke exposure, co-morbidities, or incorrect diagnosis (Table 1). Table 4 lists predisposing factors for poor asthma control, protective factors [33] and helpful strategies across the adolescent trajectory in the three developmental stages of early, middle, and late adolescence [34-47].
Table 4

Predisposing factors for poor asthma control and protective factors in adolescents according to their developmental stage [34–47]

Stage of adolescencePredisposing factors and practical mitigating strategiesProtective factors and practical enhancements to care
Early (12–14 years)Pre-occupation with pubertal changes and body imageMonitoring for linear growth velocity deviations; keeping ICS to lowest minimally effective doseImproving social perception skills

Increase exposure to positive influences, e.g., warm but firm parenting styles (authoritative), peer role models; can help safeguard against adolescents’ access to harmful situations/substances through peers

Limit consequences of immature judgement due to negative peer influences

e.g., anti-tobacco legislation, improving access to mental healthcare

Denial of vulnerability, inability to comprehend future harmsHighlighting immediate consequences, e.g., missed opportunities at social events if asthma flares up; bad breath and stained teeth from smoking
Inclination towards sensation seekingAnticipate risk taking behaviors, especially occurring in groups due to peer pressure
Middle (15–16 years)Establishing self-identity amongst peers and autonomy from parents

Consultations involving adolescent with parent first, then with adolescent alone

Ensure confidentiality, avoiding collusion with parents unless the adolescent’s safety is at risk

Improved executive processing skillsAdolescent takes responsibility for medications
Late (17–19 years)Changing functional roles with progression through higher institutions of learning and transition to work and transition to adult-centric careExplore and prepare adult care transition plans based on plans for school leaving and employmentLogic and planning improves with adolescent brain growth spurt in frontal lobesInvolve adolescent when planning for changes to medications, taking into account their preferences, e.g., switching between inhaler devices
Enhanced self-regulationFocus on maintaining smoke-free lifestyles, abstinence from harmful substances
Equip adolescent with skills to understand asthma diagnosis, triggers, and action plans

More stable peer relations

Reconnects with family

Engage peer support and family for coping

Highlight increased opportunities at social and physical activities due to improved asthma control

ICS inhaled corticosteroids

Predisposing factors for poor asthma control and protective factors in adolescents according to their developmental stage [34-47] Increase exposure to positive influences, e.g., warm but firm parenting styles (authoritative), peer role models; can help safeguard against adolescents’ access to harmful situations/substances through peers Limit consequences of immature judgement due to negative peer influences e.g., anti-tobacco legislation, improving access to mental healthcare Consultations involving adolescent with parent first, then with adolescent alone Ensure confidentiality, avoiding collusion with parents unless the adolescent’s safety is at risk More stable peer relations Reconnects with family Engage peer support and family for coping Highlight increased opportunities at social and physical activities due to improved asthma control ICS inhaled corticosteroids The advent of biologics over the past decade has provided an alternative treatment option to steroid-dependent uncontrolled asthmatics [48]. The first widely used agent, omalizumab, initially targeted at children ≥ 12 years, is currently approved for use in children ≥ 6 years old. It is indicated as add-on therapy in severe asthmatics with elevated immunoglobulin-E (IgE) levels, inadequately controlled on ICS, with aeroallergen sensitization [49]. Omalizumab is a humanized monoclonal antibody that binds selectively to IgE and involves 2–4 weekly subcutaneous administration. It has been demonstrated to improve asthma symptom control, reduce exacerbations, and minimize the need for systemic corticosteroids [50]. A course of omalizumab is long drawn and its efficacy on asthma control after cessation has been evidenced to span at least 4 years in 60% of adult patients who voluntarily discontinued omalizumab after 6 years of therapy [51]. However, this finding has yet to be substantiated in pediatric studies. In view of its substantial cost and sporadic adverse effects that include risks of anaphylaxis and malignancy, initiation of omalizumab for severe asthmatics requires careful consideration under specialist review. A review of such biologics therapy is recommended if the patient is deemed clinically unresponsive after 16 weeks [52]. Omalizumab has nevertheless been proven to be safe and well tolerated in children [53], even with treatment duration beyond 2 years [54]. Mepolizumab (targets interleukin-5) and dupilumab (antibody to interleukin-4) were more recently approved for children with refractory eosinophilic asthma [55]. Adolescents with asthma who remain uncontrolled despite treatment concordance and mitigation of risk factors or worsen upon reduction of high-dose treatment are termed “severe” [56]. Recognizing biological, psychological, and social risk factors can help formulate a risk assessment profile in the process of delivering individualized care (Table 5).
Table 5

Risk assessment profile for difficult to control adolescent asthma

BiologicalPsychologicalSocial

• Severely impaired lung function

• Past ICU admissions

• Over-usage of bronchodilators

• Frequent acute-care visits

• Early sensitization

• Lower bronchodilator response

• Increased airway variability

• Obesity

• Higher blood eosinophilia (prognostic factor for resolution of severe asthma in adolescence)

• Depression, anxiety, neurodevelopmental conditions

• Chronic stress

• Pro-inflammatory

• Risk-taking behaviors

• Poor dietary and lifestyle choices

• Poor adherence

• School

• Breakdown in peer relationships

• Family chaos

• Conflict

• Disorganized routines

• Breakdown in parent–child communication

• Smoke exposure within homes and from peers

ICU intensive care unit

Risk assessment profile for difficult to control adolescent asthma • Severely impaired lung function • Past ICU admissions • Over-usage of bronchodilators • Frequent acute-care visits • Early sensitization • Lower bronchodilator response • Increased airway variability • Obesity • Higher blood eosinophilia (prognostic factor for resolution of severe asthma in adolescence) • Depression, anxiety, neurodevelopmental conditions • Chronic stress • Pro-inflammatory • Risk-taking behaviors • Poor dietary and lifestyle choices • Poor adherence • School • Breakdown in peer relationships • Family chaos • Conflict • Disorganized routines • Breakdown in parent–child communication • Smoke exposure within homes and from peers ICU intensive care unit Biological factors associated with greater risk of cardio-respiratory morbidity and mortality include poor lung function with severely impaired airflow obstruction, commonly taken as FEV1 < 60% predicted [57, 58]. Predisposition towards impaired lung function in adulthood includes past admissions to intensive care for asthma [59], over-usage of reliever medications, increased airway variability, and low baseline FEV1 [60]. In a Swedish birth cohort study analyzing body mass index (BMI) development throughout childhood in relation to the timing of asthma onset and remission, the persistence of asthma from childhood up to 18 years of age was temporally associated with high BMI amongst females, whereas girls without asthma had the lowest BMI throughout most of their childhood. This indicates that there are overlapping risk factors for being overweight and asthmatic, starting even from infancy [61]. Weight loss interventions such as diet and exercise improve asthma-related quality of life and control in studies conducted across obese pediatric and adult groups [62] and such measures should be openly discussed from an early age. Other factors such as increased blood eosinophilia at asthma diagnosis favorably predicted resolution of severe asthma during adolescence [63]. Psychological factors and mental health play a big role in asthma outcomes. The prevalence of psychiatric comorbidities (e.g., depression and anxiety) is higher in adolescents with asthma; and quality of life and asthma control tend to be poorer when psychiatric disorders and asthma co-exist [64]. Vulnerability of the immune system related to psychological disorders can also lead to greater exacerbation risks [65]. Psychosocial stressors (e.g., poverty, violence, racism, and discrimination) adversely impact an adolescent’s asthma control. Stress exerts direct effects via a pro-inflammatory physiological state, while indirect mechanisms are attributed to risky behaviors involving sex, cigarette smoking, alcohol, substance use, and poor dietary choices [66]. Social factors, such as disorganized home environments, worsen asthma control [67]. Initiating timely support during periods of family chaos or breakdown in peer relationships [68] can steer the maladjusted adolescent away from harm. Exposure to household tobacco smoke and peer smokers influence the initiation and maintenance of smoking in adolescents with asthma [69], who model after their closest contacts.

Smoking

Individuals who smoke have a higher risk of developing asthma symptoms [70], have poorer lung function [71], and asthma flare-ups [72]. In a Brazilian study involving over 66,000 adolescents, smoke exposure amongst adolescents remains high with rates of 12–28% [73]. E-cigarette use amongst high-school teens in the United States reached 19.7% in 2020, with the majority sourcing vaping products from friends [74]. Morbidity attributed to e-cigarette or vaping product use-associated lung injury (EVALI) further compounds their dangers [75]. In the largest known case series of 98 EVALI patients (median age 21 years, range 15–53 years), most patients presented with multi-systemic involvement including respiratory, gastrointestinal, and constitutional symptoms. Notably, despite the majority having no significant past medical history other than asthma, 53% of patients required intensive care for respiratory failure [76]. Worrisome data from this cluster outbreak called for abstinence from e-cigarette use and greater awareness of its harms to avoid a rising national epidemic, resulting in a decline of cases in the United States, after peaking in September 2019 [77]. Comparatively, smoking-cessation measures are not as well studied in adolescents compared to adults [78]. Adolescents are a notoriously challenging group to enroll into formal smoking-cessation programs and have high dropout rates [79]. In a systematic review conducted involving 41 studies that recruited young people under 20 years, investigators found that beyond group-based counselling programs, other behavioral-support measures or smoking-cessation pharmacotherapeutics in young people have yet to show long-term efficacy [80]. This calls for more well-designed and adequately powered studies to advance adolescent smoking-cessation treatment programs. Nevertheless, environmental smoke exposure in a home setting is a modifiable risk factor for asthma in adolescents [81]. Smoking-cessation techniques employing motivational interviewing and cognitive behavioral techniques [82] are potentially useful if adapted to an adolescent’s level of understanding. Adolescents are likely more susceptible than chronically smoking adults to experience rapid onset of nicotine dependence, occurring within 1 month of initiation [83]. This makes the process of quitting even more challenging. Nicotine dependence is best quantified by time to first cigarette upon waking and number of cigarettes smoked per day as part of the Fagerström test [84]. The 5As (Ask, Advise, Assess, Assist, Arrange) of smoking-cessation counselling are effective in smoking prevention and abstinence when modified for adolescents [85]. Financial incentives with free cessation aids were proven to be more efficacious than usage of cessation aids alone, in employees up to 1-year post enrolment into smoking-cessation programs [86]. Incentivizing smoking cessation with vouchers rides on the developing adolescent brain’s heightened response to reward-seeking [87], outweighing the thrills sought from smoking.

Addressing Blind Spots in Transition of Care

Transitioning from child-centric to adult-oriented care requires planning and coordination [88]. Successful established pathways such as ‘Ready Steady Go’ initiated within the National Health Service, United Kingdom [89], begins this staged process from age 11 years old, with generic patient and parent questionnaires applicable across all specialties [90]. Caregivers’ and patients’ disease knowledge and attitudes must first be addressed, followed by empowering the young person with self-help skills, all of which requires multidisciplinary healthcare support [91]. Best practices for transitional health care include appropriate parental involvement and promotion of the adolescents’ self-efficacy in managing their health [92]. Adopting a flexible approach in the culmination to adult-oriented care from 16 to 19 years old onwards takes into consideration their transition readiness, school-leaving plans, and varied levels of self-efficacy [93]. Reaching this milestone in care should not be reliant on chronological age alone or orchestrated out of physician frustration towards an adolescent with difficult to control asthma [94]. An oppositional adolescent allowed to “drop out” of the healthcare system faces missed opportunities in addressing risks for severe exacerbations [95]. Generally, asthmatic adolescents who do not require daily medications can be transited to primary healthcare whilst some may require a specialist referral for shared care [96]. Those requiring daily medications with greater disease burden and family vulnerabilities can be transited to the adult respiratory specialist equipped with multi-disciplinary resources such as a specialist nurse practitioner trained in adolescent care to facilitate the process [97]. During this challenging pandemic, telemedicine has become integral to asthma care to allow continued engagement and adherence to outpatient appointments [98]. Furthermore, joint video consultations [99] with pediatric and adult medical practitioners can help orientate the patient amidst movement restrictions across institutions. However, for families unfamiliar with telemedicine, the option to switch to face-to-face visits should always still be made available to them. Care should be taken to avoid loading already-burdened families of chronic disease patients with the stress of partaking in technology that may remain inaccessible to them [100].

Future Directions in Caring for Adolescents with Asthma and Concluding Remarks

The management of adolescent asthma should be supported by population, community- and school-based strategies in tandem with the efforts of healthcare providers (Fig. 1). Marketing efforts by tobacco-sponsored industry increase the youth’s susceptibility to smoking [101]. Raising the minimum legal age for sale of tobacco and e-cigarette products from 18 to 21 years [102] and launching youth e-cigarette prevention campaigns [103] are helpful counter-marketing measures [104]. School-based [105] and peer-led programs [106] have provided beneficial support for adolescents with asthma. Self-perceived under-performance in school and lack of participation in physical activities are more likely in asthmatics than in others [107]. As the burden of chronic disease competes with academic attainment, schools and healthcare teams must link up [108], aiming to minimize school absenteeism attributed to appointments and flare-ups. Whilst asthma health technology [109] is eagerly embraced by adolescents, more evidence is required in proving that applications [110] for medication adherence, disease monitoring, and health literacy are effective. Human–computer interactions for inhaler technique competency, peak flow monitoring, and medication reminders are promising and complement current practices [111, 112] but require further patient engagement to fulfil unmet needs [113].
Fig. 1

Levels of care in holistic asthma management for adolescents. Levels of asthma care range from large-scale population-based strategies to smaller-scale school and healthcare providers’ efforts, followed by specific family- and peer-support measures

Levels of care in holistic asthma management for adolescents. Levels of asthma care range from large-scale population-based strategies to smaller-scale school and healthcare providers’ efforts, followed by specific family- and peer-support measures A rewarding experience awaits as we journey with adolescents from asthma diagnosis to adult transition. Continued engagement with schools and communities can provide a safer springboard for individuals leaving childhood into adolescence, as they transition towards better asthma outcomes in adulthood.
Adolescents with asthma face unique challenges, exacerbated by their pre-occupation with body image, self-identity creation, need for peer acceptance, and risk-taking behaviors.
Diagnostic conundrums exist in asthma and reliance on a good clinical history, physical examination, objective tests, and response to treatment assessed over time is crucial for an accurate diagnosis.
Understanding an adolescent according to their stage of development in early, middle, and late adolescence can help formulate risk factors and protective mechanisms in their asthma care.
Biological, psychological, and social factors affect an adolescent with difficult-to-treat and severe asthma.
Transition of care to adult-oriented settings is a planned and coordinated process based upon the individual’s level of self-efficacy and should not be orchestrated out of physician frustration.
  77 in total

1.  Not all wheeze is asthma: time for patients to exercise their rights.

Authors:  J H Hull
Journal:  Thorax       Date:  2014-11-14       Impact factor: 9.139

Review 2.  Diagnostic criteria for the classification of vocal cord dysfunction.

Authors:  Michael J Morris; Kent L Christopher
Journal:  Chest       Date:  2010-11       Impact factor: 9.410

Review 3.  Exercise-induced laryngeal obstruction in children and adolescents: are we listening?

Authors:  Liam Welsh; Alessandra Giannini; John Massie
Journal:  Arch Dis Child Educ Pract Ed       Date:  2020-10-19       Impact factor: 1.309

4.  Puberty and prognosis of asthma and bronchial hyper-reactivity.

Authors:  T Nicolai; S Illi; J Tenbörg; W Kiess; E v Mutius
Journal:  Pediatr Allergy Immunol       Date:  2001-06       Impact factor: 6.377

5.  The relationship of anxiety disorders, anxiety sensitivity and pulmonary dysfunction with dyspnea-related distress and avoidance.

Authors:  Naomi M Simon; Alexander M Weiss; Richard Kradin; Karleyton C Evans; Hannah E Reese; Michael W Otto; Julia E Oppenheimer; Jordan W Smoller; Alyson Zalta; John J Worthington; Mark H Pollack
Journal:  J Nerv Ment Dis       Date:  2006-12       Impact factor: 2.254

6.  Diagnostic accuracy of the bronchodilator response in children.

Authors:  Sze Man Tse; Diane R Gold; Joanne E Sordillo; Elaine B Hoffman; Matthew W Gillman; Sheryl L Rifas-Shiman; Anne L Fuhlbrigge; Kelan G Tantisira; Scott T Weiss; Augusto A Litonjua
Journal:  J Allergy Clin Immunol       Date:  2013-05-14       Impact factor: 10.793

Review 7.  Pubertal transitions in health.

Authors:  George C Patton; Russell Viner
Journal:  Lancet       Date:  2007-03-31       Impact factor: 79.321

Review 8.  Adolescents with a chronic condition: challenges living, challenges treating.

Authors:  Susan M Sawyer; Sarah Drew; Michele S Yeo; Maria T Britto
Journal:  Lancet       Date:  2007-04-28       Impact factor: 79.321

Review 9.  Inducible laryngeal obstruction: an official joint European Respiratory Society and European Laryngological Society statement.

Authors:  Thomas Halvorsen; Emil Schwarz Walsted; Caterina Bucca; Andrew Bush; Giovanna Cantarella; Gerhard Friedrich; Felix J F Herth; James H Hull; Harald Jung; Robert Maat; Leif Nordang; Marc Remacle; Niels Rasmussen; Janet A Wilson; John-Helge Heimdal
Journal:  Eur Respir J       Date:  2017-09-09       Impact factor: 16.671

Review 10.  Epidemiology of Asthma in Children and Adults.

Authors:  Shyamali C Dharmage; Jennifer L Perret; Adnan Custovic
Journal:  Front Pediatr       Date:  2019-06-18       Impact factor: 3.418

View more
  1 in total

1.  A real-world implementation of asthma clinic: Make it easy for asthma with Easy Asthma Clinic.

Authors:  Watchara Boonsawat; Kittisak Sawanyawisuth
Journal:  World Allergy Organ J       Date:  2022-10-07       Impact factor: 5.516

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.